[go: up one dir, main page]

WO2000025754A3 - Solid oral dosage forms containing alginic acid and famotidine - Google Patents

Solid oral dosage forms containing alginic acid and famotidine Download PDF

Info

Publication number
WO2000025754A3
WO2000025754A3 PCT/US1999/025250 US9925250W WO0025754A3 WO 2000025754 A3 WO2000025754 A3 WO 2000025754A3 US 9925250 W US9925250 W US 9925250W WO 0025754 A3 WO0025754 A3 WO 0025754A3
Authority
WO
WIPO (PCT)
Prior art keywords
alginic acid
famotidine
oral dosage
solid oral
dosage forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/025250
Other languages
French (fr)
Other versions
WO2000025754A2 (en
Inventor
Edward J Roche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenvue Brands LLC
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Priority to AU14536/00A priority Critical patent/AU1453600A/en
Publication of WO2000025754A2 publication Critical patent/WO2000025754A2/en
Publication of WO2000025754A3 publication Critical patent/WO2000025754A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides solid oral dosage forms for treating gastric disorders, comprising effective doses of (a) famotidine or pharmaceutically acceptable salt thereof, and (b) alginic acid, wherein the famotidine, or pharmaceutically acceptable salt thereof, and alginic acid are physically separated by a pharmaceutically acceptable barrier which is impermeable to alginic acid. This invention also provides methods for manufacturing the instant solid oral dosage form, and therapeutic and prophylactic methods using same.
PCT/US1999/025250 1998-11-04 1999-11-03 Solid oral dosage forms containing alginic acid and famotidine Ceased WO2000025754A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU14536/00A AU1453600A (en) 1998-11-04 1999-11-03 Solid oral dosage forms containing alginic acid and famotidine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10704598P 1998-11-04 1998-11-04
US06/107,045 1998-11-04

Publications (2)

Publication Number Publication Date
WO2000025754A2 WO2000025754A2 (en) 2000-05-11
WO2000025754A3 true WO2000025754A3 (en) 2000-09-08

Family

ID=22314559

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/025250 Ceased WO2000025754A2 (en) 1998-11-04 1999-11-03 Solid oral dosage forms containing alginic acid and famotidine

Country Status (2)

Country Link
AU (1) AU1453600A (en)
WO (1) WO2000025754A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2273409T3 (en) 1997-03-28 2007-05-01 Eisai Co., Ltd. ORAL MEDICINES THAT PREVENT UNFORGETTABLE AND SIMILAR FLAVOR.
DK1260215T3 (en) 2000-03-01 2009-11-09 Eisai R&D Man Co Ltd Rapid disintegrating tablet containing polyvinyl alcohol
US6623785B2 (en) 2001-06-07 2003-09-23 Hewlett-Packard Development Company, L.P. Pharmaceutical dispensing apparatus and method
WO2005065639A2 (en) * 2003-11-21 2005-07-21 Torrent Pharmaceuticals Limited Novel pharmaceutical compositions
JO3112B1 (en) 2010-03-29 2017-09-20 Ferring Bv A fast dissolving pharmaceutical composition
US8946153B2 (en) 2010-03-29 2015-02-03 Ferring B.V. Fast dissolving pharmaceutical composition
US9731018B2 (en) 2011-09-16 2017-08-15 Ferring B.V. Fast dissolving pharmaceutical composition
WO2017091166A1 (en) * 2015-11-26 2017-06-01 Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. Stable pharmaceutical compositions and process for their preparation
BR112023019653A2 (en) * 2021-03-24 2023-10-31 Johnson & Johnson Consumer Inc COATED FAMOTIDINE PARTICLE

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260072A (en) * 1990-08-30 1993-11-09 Mcneil-Ppc, Inc. Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
EP0600725A1 (en) * 1992-12-01 1994-06-08 McNEIL-PPC, INC. Pharmaceutical compositions containing a guanidinothiazole and antacids
WO1995001780A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-alginate combinations
WO1995001795A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-alginate-antacid combinations
WO1996015775A1 (en) * 1994-11-21 1996-05-30 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260072A (en) * 1990-08-30 1993-11-09 Mcneil-Ppc, Inc. Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
EP0600725A1 (en) * 1992-12-01 1994-06-08 McNEIL-PPC, INC. Pharmaceutical compositions containing a guanidinothiazole and antacids
WO1995001780A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-alginate combinations
WO1995001795A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-alginate-antacid combinations
WO1996015775A1 (en) * 1994-11-21 1996-05-30 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
WO2000025754A2 (en) 2000-05-11
AU1453600A (en) 2000-05-22

Similar Documents

Publication Publication Date Title
WO1999044581A3 (en) Pharmaceutical composition of topiramate
WO1997038679A3 (en) Fast disintegrating oral dosage form
CA2427815A1 (en) Controlled release hydrocodone formulations
WO2001027119A3 (en) Substance library containing bicyclic imidazo-5-yl-amines and/or bicyclic imidazo-3-yl-amines
PT1441705E (en) Solid, stabilized, prompt- and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs
PL356358A1 (en) Solid dosage form of someticone for oral administration
HUP0302131A2 (en) Pharmaceutical tramadol salts, pharmaceutical compositions containing them
HK1041224A1 (en) New pharmaceutical formulation
EE04800B1 (en) Oral dosage form for acid unstable active ingredient, unit dosage form, method of preparation and use, and method for oral dosage form
WO2001001973A8 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
HRP20000142B1 (en) Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
MXPA03006476A (en) Pharmaceutical dosage forms of epothilones for oral administration.
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
WO2002094774A3 (en) Oxcarbazepine dosage forms
HK60189A (en) Medicaments for paf acether induced maladies
PL333524A1 (en) Improved prolonged release pharmaceutic preparation for administration of nephadosone, oral dosage form thereof and improved nephadosone administration method
CA2252515A1 (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
WO2001098279A3 (en) Bis-arylsulfones
HK1052868A1 (en) Solid valsartan pharmaceutical compositions
WO2000025754A3 (en) Solid oral dosage forms containing alginic acid and famotidine
EP1440691A3 (en) Treatment of neurotic disorders
WO2003037863A3 (en) Substituted indoles, method for production and use thereof for the inhibition of pain
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
WO2004087880A3 (en) Compounds and their use to treat diabetes and related disorders
WO2005051350A3 (en) Water dispersible tablet

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 14536

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase